Alternating Treatment With Fruquintinib and Bevacizumab Plus Capecitabine as Maintenance Therapy After First-Line Treatment in Metastatic Colorectal Cancer

Metastatic Colorectal Cancer Clinical Trial

Official title:

Alternating Treatment With Fruquintinib and Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer: A Multi-center, Parallel-group, Phase II Study.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05659290
• Other study ID #: NFEC-2022-479
• Status: Recruiting
• Phase: Phase 2
• Start date: January 2023
• Est. completion date: December 2025

Study information

• Verified date: December 2022
• Source: Nanfang Hospital of Southern Medical University
• Contact: Wangjun Liao, MD, PhD
• Phone: 86-20-62787731
• Email: nfyyliaowj[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label, multicenter, randomized parallel-group phase 2 study evaluating the efficacy and safety of Fruquintinib alternating with Bevacizumab plus Capecitabine versus Bevacizumab plus Capecitabine as maintenance therapy following first-line treatment for metastatic colorectal cancer. Approximately 40 patients with metastatic colorectal cancer who have achieved partial remission after completing 8 cycles of standard first-line chemotherapy (FOLFOX combined with Bevacizumab) but are still in un-resectable state will be assigned to 2 maintenance treatment groups by randomization in a 1:1 ratio to receive Fruquintinib alternating with Bevacizumab plus Capecitabine (Arm A) or Bevacizumab plus Capecitabine (Arm B). The study contains a safety lead-in phase in which the safety and efficacy of Fruquintinib alternating with Bevacizumab plus Capecitabine will be assessed in approximately 20 patients. All patients from Arm A and Arm B will be treated until unacceptable toxicity, withdrawal of informed consent, death, or other criteria for ending the study (whichever occurs earlier). The study will evaluate PFS, ORR, DCR, OS and safety.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: December 2025
• Est. primary completion date: December 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Patients voluntarily participated in the study, signed the informed consent, and had good compliance;

2. Age 18-75 (including 18 and 75), gender is not limited;

3. Histologically and/or cytologically confirmed metastatic colorectal cancer (stage IV);

4. The patient with at least one measurable lesion (RECIST 1.1) achieved partial remission after 8 cycles of first-line standard chemotherapy (FOLFOX combined with bevacizumab), and the disease remained in an unresectable state.

5. ECOG performance status of 0-2 points;

6. Expected survival =12 weeks;

7. Blood test (without blood transfusion within 14 days) 1) Neutrophil absolute value =1.5×10^9/L, platelet =100×10^9/L, hemoglobin =90g/L); 2) Liver function test (aspartate aminotransferase and glutamate aminotransferase =3×ULN, bilirubin =1.5×ULN; In case of liver metastasis, AST and ALT=5×ULN); 3) Renal function (serum creatinine =1.5×ULN, or creatinine clearance (CCr)=60ml/min);

8. Men and women of childbearing age must use effective contraceptive methods.

Exclusion Criteria:

1. Received major surgery within 4 weeks prior to the first drug administration; radiotherapy, radiofrequency ablation, chemotherapy, immunotherapy or molecular targeted therapy for tumors within 2 weeks, and other investigational drugs;

2. Previously received anti-vascular small-molecule targeted drug therapy, such as fuquinitinib, regofenib, etc.;

3. A history of severe intolerance to bevacizumab and capecitabine or 5-Fu (i.e., grade 4 toxicity of one of these drugs; Class 3-4 toxicity of other co-administered drugs is not excluded);

4. Known brain or meningeal metastases:

5. Have hypertension that is not well controlled by antihypertensive medications (systolic blood pressure =140 mmHg or diastolic blood pressure =90 mmHg);

6. Obvious clinical bleeding symptoms or obvious bleeding tendency and hemoptysis within 3 months prior to treatment. Or treatment of venous/venous thrombosis events within the preceding 6 months, such as cerebrovascular accidents (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism; Long-term anticoagulant therapy with warfarin or heparin, or long-term antiplatelet therapy (aspirin =300 mg/day or clopidogrel =75 mg/day) is required;

7. Active heart disease, including myocardial infarction, severe/unstable angina in the 6 months prior to treatment. Echocardiography showed that the left ventricular ejection fraction was less than 50%, indicating poor arrhythmia control.

8. The patient had other malignancies (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix) within the previous 5 years or at the same time;

9. Known allergy to the study drug or any of its excipients;

10. Severe active infection or uncontrolled infection;

11. Any other disease, a clinically significant metabolic abnormality, abnormal physical examination or abnormal laboratory examination, for which, in the investigator's judgment, there is reason to suspect that the patient has a disease or condition unsuitable for the use of the investigational agent;

12. Urine routine indicated urine protein =2+, and 24 hours urine protein quantity >1.0g.

Related Conditions & MeSH terms

• Colorectal Neoplasms
• Metastatic Colorectal Cancer

Intervention

Drug:
• Fruquintinib alternating with Bevacizumab plus Capecitabine
Maintenance therapy with Fruquintinib 5mg, orally, once daily, d1-14, 2 weeks on/ 1 week off, q3w, followed by Bevacizumab 7.5 mg/kg, iv.gtt,d1,q3w + Capecitabine 850 mg/m2, orally, twice daily, d1-14, q3w; every 6 weeks as a treatment cycle; until unacceptable toxicity, withdrawal of informed consent, death, or other criteria for ending the study (whichever occurs earlier).
• Bevacizumab plus Capecitabine
Maintenance therapy with Bevacizumab 7.5 mg/kg, iv.gtt,d1,q3w + Capecitabine 850 mg/m2, orally, twice daily, d1-14, q3w; every 3 weeks as a treatment cycle; until unacceptable toxicity, withdrawal of informed consent, death, or other criteria for ending the study (whichever occurs earlier).

Locations

Country	Name	City	State
China	Nanfang Hospital, Southern Medical University	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Nanfang Hospital of Southern Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-free Survival (PFS)	Defined as the time between the onset of PD or death when a patient first receives the study drug, whichever occurs first.	3 years
Secondary	Objective Response Rate (ORR)	Defined as the proportion of patients who achieved complete response (CR) or partial response (PR)	3 years
Secondary	Disease Control Rate (DCR)	Defined as the proportion of patients achieving CR, PR, or stable disease (SD).	3 years
Secondary	Overall Survival (OS)	Defined as the time between the patient's first receipt of the study drug to death.	3 years